Patrick J. Halloran
Patrick J. Halloran, Ph.D.
Dr. Patrick Halloran is a registered patent attorney and has served as an advisor and counselor in the pharmaceutical, biotechnology, and life science fields for more than 25 years. His diverse experience involve counseling large, mid-size, and start-up pharmaceutical and biotechnology companies, as well as universities and investment groups. His expansive technical, legal, and industry expertise has guided client work on in-license and out-license targets, freedom-to-operate and validity opinions, infringement assertions, trademark registration, and patent prosecution.
Dr. Halloran began his intellectual property career as a scientific advisor in 1996 at Banner & Witcoff, Ltd. and soon thereafter joined McDonnell, Boehnen, Hulbert & Berghoff, LLP. In 1997, Dr. Halloran obtained his registration to practice before the United States Patent and Trademark Office (Reg. No. 41,053). He graduated from Chicago-Kent College of Law in 1999 and was admitted to practice law in the State of Illinois. In 2001, he joined Aventis Pasteur, Inc. (now Sanofi Pasteur, Inc.), eventually becoming Senior Director of Intellectual Property. In that role, he was responsible for domestic and international intellectual property issues relating to various projects within the company. Throughout his career, Dr. Halloran has worked extensively with outside counsel from other regions and countries including Australia, Europe, Canada, China, India, Japan, and New Zealand and Singapore.
Dr. Halloran earned a Ph.D. in Microbiology and Immunology from The University of Health Sciences / The Chicago Medical School (now the Rosalind Franklin Institute (North Chicago, IL) (1994)). His doctoral project related to the biochemical characterization and cloning of the cDNA encoding a porcine cytolytic trigger molecule which was identified as an Fc-g receptor (e.g., Halloran, et al. J. Immunol. 153(6): 2631-41 (Sept. 15, 1994) and Halloran, et al. Cell. Immunol. 158(2): 400-13 (Oct. 15, 1994)). During his graduate studies, Dr. Halloran served as Secretary (1989), Vice-President (1990), and President (1991-1993) of the Graduate Student Association and won first place in the 1994 Sigma Xi Research Society research competiton (“Identification of the Porcine Cytolytic Trigger Molecule G7 as an Fc-g receptor”). He also performed post-doctoral studies at The National Cancer Institute (Frederick, MD) from 1994-1996 relating to novel approaches for gene therapy of melanoma (Siders, et al. Cancer Res. 56(24): 5638-46 (Dec. 15, 1996); Halloran, et al. Cancer Res. 58(17): 3855-65 (Sept. 1, 1998); and, Siders et al. Cancer Gene Ther. 5(5): 281-91 (Sept.-Oct. 1998)). He also has a B.A. in Biology from Augustana College (Rock Island, IL; 1989) where he was a member of the Beta Beta Beta Biological Honor Society, the Educational Policies Committee, and two NCAA Division III National Championship football teams.
- Chicago-Kent College of Law, Illinois Institute of Technology (J.D.)
- Chicago Medical School at Rosalind Franklin University U-Med & Science (Ph.D.)
Microbiology and Immunology
- Augustana College (B.A.)
- U.S. Patent and Trademark Office
Representative Presentations and Publications:
- Vacchiano, E. and Halloran, P.J. Amarin’s U.S. Patent protection for Vascepa. Seeking Alpha (Nov. 30, 2018)
- Siders W.M., Halloran, P.J., Fenton R.G. Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus. Cancer Gene Ther. 1998 Sep-Oct; 5(5):281-91.
- Halloran P.J., Fenton R.G. Irreversible G2-M arrest and cytoskeletal reorganization induced by cytotoxic nucleoside analogues. Cancer Res. 1998 Sept 1:58(17):3855-65.